Renal Denervation Devices

Global Renal Denervation Devices Market to Reach US$2.2 Billion by 2030

The global market for Renal Denervation Devices estimated at US$1.1 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2024-2030. Percutaneous Renal Denervation, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$913.1 Million by the end of the analysis period. Growth in the Radiofrequency Renal Denervation segment is estimated at 16.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$288.7 Million While China is Forecast to Grow at 17.3% CAGR

The Renal Denervation Devices market in the U.S. is estimated at US$288.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$463.3 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 11.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global “Renal Denervation Devices” Market – Key Trends & Drivers Summarized

Why Are Renal Denervation Devices Being Hailed as a Breakthrough in Hypertension Management?
Renal denervation (RDN) devices are poised to revolutionize the treatment of drug-resistant hypertension, one of the most prevalent and persistent health challenges worldwide. These devices use radiofrequency, ultrasound, or chemical ablation to disrupt overactive renal sympathetic nerves—nerves that contribute significantly to elevated blood pressure. Despite multiple pharmacological options, many patients struggle to achieve target blood pressure levels due to poor medication adherence or ineffectiveness of drug therapy. RDN provides a minimally invasive, long-lasting solution, particularly appealing to patients and physicians seeking alternatives to lifelong drug regimens. As hypertension remains a leading cause of cardiovascular disease and mortality globally, the clinical relevance and market potential for RDN devices are substantial.

How Are Clinical Trials and Regulatory Milestones Shaping the RDN Market?
Clinical validation and regulatory approvals are key milestones driving confidence and adoption in the renal denervation market. Recent trials like SPYRAL HTN-OFF MED and RADIANCE-HTN SOLO have demonstrated significant and sustained reductions in systolic blood pressure with favorable safety profiles. These results have helped address early skepticism and reignited interest among cardiologists and interventional radiologists. Regulatory bodies in Europe have already approved some RDN systems, while U.S. FDA approvals are on the horizon, following promising data. Continued research into patient selection criteria, long-term outcomes, and potential synergies with pharmacological treatments is expected to accelerate adoption. These advances are also expanding RDN’s potential use in adjacent indications, such as heart failure and metabolic syndrome.

Which Market Forces and Healthcare Trends Are Driving RDN Device Demand?
The demand for renal denervation devices is rising in tandem with global hypertension prevalence, aging populations, and increasing awareness of cardiovascular risks. Healthcare providers are increasingly exploring device-based solutions to improve patient adherence and reduce the overall burden of medication management. Economic pressures and payer focus on long-term outcomes are aligning well with RDN’s promise of durable blood pressure control. Additionally, the rise in outpatient surgical centers and advancements in catheter-based procedures are making RDN more accessible and cost-effective. Patient interest in non-drug therapies—especially in regions with high treatment fatigue and polypharmacy challenges—is further accelerating interest in RDN.

The Growth in the Renal Denervation Devices Market Is Driven by Clinical Efficacy, Aging Populations, and a Shift Toward Non-Pharmacologic Interventions
The renal denervation market is expanding rapidly, fueled by several converging trends. The success of key clinical trials has established RDN as a credible alternative for patients with resistant hypertension, unlocking regulatory approvals and commercial traction. An aging global population—more prone to hypertension and cardiovascular comorbidities—is expanding the addressable market. Moreover, healthcare systems are increasingly valuing non-pharmacological interventions that offer long-term outcomes and reduced medication dependency. Procedural advancements, favorable reimbursement trends, and growing specialist adoption are further strengthening the market. Finally, patient-centric care models that prioritize lifestyle-friendly, one-time interventions are supporting a shift toward broader RDN device adoption across global health systems.

SCOPE OF STUDY:

The report analyzes the Renal Denervation Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Procedure Type (Percutaneous Renal Denervation, Radiofrequency Renal Denervation, Ultrasound Renal Denervation, Other Procedure Types); End-User (Hospitals, Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Ablative Solutions, Inc.
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cardiosonic Ltd.
• Cordis Corporation
• Covidien PLC
• DeepQure Inc.
• Johnson & Johnson Services, Inc.
• Kona Medical, Inc.
• Medtronic PLC
• Mercator MedSystems, Inc.
• Miracor Medical SA
• Otsuka Medical Devices Co., Ltd.
• ReCor Medical, Inc.
• Renal Dynamics Ltd.
• SoniVie Ltd.
• St. Jude Medical, Inc.
• Symple Surgical, Inc.
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.